Holen Sie sich die Stockscreener-App
29.68
2.82%
-0.86
Handel nachbörslich:
29.68
Schlusskurs vom Vortag:
$30.54
Offen:
$30.57
24-Stunden-Volumen:
291.07K
Relative Volume:
1.15
Marktkapitalisierung:
$2.07B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-198.12M
KGV:
-8.8095
EPS:
-3.3691
Netto-Cashflow:
$-159.74M
1W Leistung:
-2.37%
1M Leistung:
-1.20%
6M Leistung:
+19.53%
1J Leistung:
+81.09%
1-Tages-Spanne:
$29.51
$31.00
1-Wochen-Bereich:
$28.33
$31.00
52-Wochen-Spanne:
$15.46
$33.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
29.68 | 2.13B | 0 | -198.12M | -159.74M | -3.3691 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris (PHVS) technical ops chief sells 8,748 shares in open market - Stock Titan
Pharvaris (PHVS) CCO Souverijns sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
Pharvaris N.V. (PHVS) Fell -5.23% — Is a Recovery Ahead? 2026-05-18{涓偂鍓爣棰榼 - Newser
Pharvaris N.V. (PHVS) Delivers Q1 2026 Beat — EPS $-0.59 vs $-0.73 ExpectedShare Dilution Risk - Newser
The Bull Case For Pharvaris (PHVS) Could Change Following Major Equity Raise And NDA ProgressLearn Why - simplywall.st
Viking Global affiliates hold 3.65M shares of Pharvaris (PHVS) after amendment - Stock Titan
PHVS (NASDAQ: PHVS) reports 10b5-1 sales of 23,333; 2,292 RSUs - Stock Titan
Affiliate files notice to sell 4,667 & 4,137 shares (NASDAQ: PHVS) - Stock Titan
Pharvaris N.V. (PHVS) Q4 2025 Earnings Miss: EPS $-0.72 vs $-0.63 ExpectedEPS Surprise History - Newser
Discipline and Rules-Based Execution in PHVS Response - Stock Traders Daily
Why Pharvaris Shares Are Suddenly Sliding Today - TipRanks
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case - Yahoo Finance
Pharvaris (PHVS) CMO reports 226 shares withheld for RSU taxes - Stock Titan
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.57, Implies 49% Upside - TradingView
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.51, Implies 49% Upside - TradingView
Citizens lowers Pharvaris stock price target to $74 on valuation By Investing.com - Investing.com South Africa
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.6, Implies 49% Upside - TradingView
Citizens lowers Pharvaris stock price target to $74 on valuation - Investing.com
Pharvaris Executive Sells Common Shares Following Option Exercise - HarianBasis.co
Pharvaris Prices $115 Million Underwritten Offering of Ordinary Shares - Global Legal Chronicle
Earnings Flash (PHVS) Pharvaris Posts Q1 Per Share Loss 0.59 Euro, vs. FactSet Est of 0.71 Euro Loss - marketscreener.com
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Pharvaris (NASDAQ: PHVS) posts Q1 loss, funds pipeline into 2028 - Stock Titan
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pharvaris earnings in focus as HAE drug candidate nears key trials By Investing.com - Investing.com South Africa
Pharvaris earnings in focus as HAE drug candidate nears key trials - Investing.com Nigeria
TradingKey - TradingKey
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Pharvaris completes $132 million share offering on Nasdaq - Investing.com UK
Pharvaris completes $132 million share offering on Nasdaq By Investing.com - Investing.com South Africa
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out - TipRanks
[6-K] Pharvaris N.V. Current Report (Foreign Issuer) | PHVS SEC FilingForm 6-K - Stock Titan
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Press Release: Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Pharvaris prices $115M stock offering - msn.com
The Bull Case For Pharvaris (PHVS) Could Change Following Dilutive US$115 Million Equity RaiseLearn Why - simplywall.st
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):